The global in-vitro toxicology testing market size was estimated to be USD 31.34 billion in 2023 and is expected to reach at USD 103.27 billion by 2034 with a CAGR of 11.45% during the forecast period 2024-2034. Increasing cost of animal testing is more expensive for evaluating toxicity, & it raises ethical and societal issues as well, surge in multiple drug discovery processes, growing government initiatives focused on banning animal testing, rising funding for development of in-vitro test approaches by government & private bodies, increasing need of in-vitro assays & toxicology testing, the availability of several cutting-edge techniques, including in-silico simulated models & databases for research of large substances to comprehend and analyse the toxicity, and rising developments in toxicology research such as use of 3D in-vitro models are some of the key factors boosting the market growth.
Rising collaborations within market players for the development of new assays is predicted to boost the market growth during the forecast period. To detect the toxic potential of compounds at the outset of the drug discovery phase, a range of specialized scientific skills and customized solutions are necessary to address particular toxicological risks. For instance, in March 2023, The Institute for In Vitro Sciences (IIVS) has entered into a licensing agreement with Toxys, enabling IIVS to provide the ToxTracker® assay.
By technology, cell culture technology was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to the rising demand for early-stage drug toxicity testing, growing adoption of cell culture technology by healthcare academic institutions, biotechnology industries, & pharmaceutical manufacturers, and increasing initiatives by leading market players. For instance, in October 2022, To support customers in providing cutting-edge drugs to patients, Thermo Fisher Scientific Inc. has plans to enhance its Highland Heights, Kentucky, laboratory facilities. The existing facility, which encompasses central laboratory and biomarker operations, offers biopharmaceutical clients top-tier laboratory services to expedite drug development. This initiative has facilitated the company's expansion in the clinical diagnostics sector across multiple global regions and bolstered its international market presence. Additionally, high throughput technology is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of high throughput technologies (HTTs) in the pharmaceutical industry, and surge in need for toxicity failure burden reduction & a variety of medications in the product pipeline.
By application, systemic toxicology was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to the comprehension of side effects that appear quite soon after taking a medicine and growing acquisitions within market players. For instance, in June 2023, Lonza, a worldwide manufacturing collaborator for the pharmaceutical, biotechnology, and nutraceutical sectors, has reported its acquisition of Synaffix B.V. (Synaffix), a biotechnology firm dedicated to advancing its clinical-stage technology platform for the development of ADCs. This acquisition is expected to facilitate Lonza's global expansion efforts. Additionally, dermal toxicity is predicted to grow at fastest CAGR during the forecast period owing to the surge in governing framework for cosmetics toxicity testing, and increasing improvements in in vitro methods for determining skin toxicity risk.
By method, cellular assay was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to the wide availability of cell cultures for analysing the pharmacokinetic profile of drugs, surge in early-stage drug toxicity profiling, rising technological advances such as automation, increasing efforts by manufacturers for the development of novel cellular assays, and growing mergers & acquisitions within market players. For instance, in September 2022, BioIVT announced the successful purchase of XenoTech, underscoring their commitment to providing comprehensive research solutions and services to biopharmaceutical clients, aiming to advance drug development and diagnostic investigations. Through the integration of XenoTech's specialized knowledge and product offerings, including microsomes and other laboratory models, BioIVT aims to strengthen its capacities in in-vitro toxicology assessments and pharmaceutical research. This move is expected to amplify BioIVT's competitive advantage within the sector. Additionally, in-silico is predicted to grow at fastest CAGR during the forecast period owing to the growing implementation of analytical method using computational tools for accurate and effective safety evaluation, and increasing technological developments.
By end-user, pharmaceutical industry was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to a lot of toxicological testing is done to examine the pharmacokinetic characteristics of pharmaceutical medications, rising research & development for new drugs. Additionally, diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the growing number of diagnostic devices, increasing focus on development of innovative solutions for virus detection, and rising collaborations within market players. For instance, in March 2022, Laboratory Corporation of America Holdings (LabCorp) completed the acquisition of diagnostic clinical laboratory services provided by AtlantiCare.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing government funding for research & development activities, rising healthcare expenditure, growing adoption of toxicology testing, surge in launch of biologics by biopharmaceutical companies, and increasing mergers & acquisitions within market players. For instance, in June 2023, Lonza, a global manufacturing partner for pharmaceuticals, biotechnology, and nutraceuticals, has officially acquired Synaffix B.V., a biotechnology company specializing in advancing its clinical-stage technology platform for developing antibody-drug conjugates (ADCs). This strategic move is expected to support Lonza's expansion on a global scale. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising development of health care settings, growing geriatric population, surge in government investment for enhancing technology & development, and increasing collaborations within market players. For instance, in July 2023, InSphero AG and Cosmo Bio Co., Ltd. have formed a strategic partnership to distribute InSphero's innovative product range in Japan. This collaboration, which is now in effect, designates Cosmo Bio as the sole distributor of InSphero's 3D cell-based assay solutions throughout the Japanese market.
Rising collaborations within market players for the development of new assays is predicted to boost the market growth during the forecast period. To detect the toxic potential of compounds at the outset of the drug discovery phase, a range of specialized scientific skills and customized solutions are necessary to address particular toxicological risks. For instance, in March 2023, The Institute for In Vitro Sciences (IIVS) has entered into a licensing agreement with Toxys, enabling IIVS to provide the ToxTracker® assay.
By technology, cell culture technology was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to the rising demand for early-stage drug toxicity testing, growing adoption of cell culture technology by healthcare academic institutions, biotechnology industries, & pharmaceutical manufacturers, and increasing initiatives by leading market players. For instance, in October 2022, To support customers in providing cutting-edge drugs to patients, Thermo Fisher Scientific Inc. has plans to enhance its Highland Heights, Kentucky, laboratory facilities. The existing facility, which encompasses central laboratory and biomarker operations, offers biopharmaceutical clients top-tier laboratory services to expedite drug development. This initiative has facilitated the company's expansion in the clinical diagnostics sector across multiple global regions and bolstered its international market presence. Additionally, high throughput technology is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of high throughput technologies (HTTs) in the pharmaceutical industry, and surge in need for toxicity failure burden reduction & a variety of medications in the product pipeline.
By application, systemic toxicology was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to the comprehension of side effects that appear quite soon after taking a medicine and growing acquisitions within market players. For instance, in June 2023, Lonza, a worldwide manufacturing collaborator for the pharmaceutical, biotechnology, and nutraceutical sectors, has reported its acquisition of Synaffix B.V. (Synaffix), a biotechnology firm dedicated to advancing its clinical-stage technology platform for the development of ADCs. This acquisition is expected to facilitate Lonza's global expansion efforts. Additionally, dermal toxicity is predicted to grow at fastest CAGR during the forecast period owing to the surge in governing framework for cosmetics toxicity testing, and increasing improvements in in vitro methods for determining skin toxicity risk.
By method, cellular assay was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to the wide availability of cell cultures for analysing the pharmacokinetic profile of drugs, surge in early-stage drug toxicity profiling, rising technological advances such as automation, increasing efforts by manufacturers for the development of novel cellular assays, and growing mergers & acquisitions within market players. For instance, in September 2022, BioIVT announced the successful purchase of XenoTech, underscoring their commitment to providing comprehensive research solutions and services to biopharmaceutical clients, aiming to advance drug development and diagnostic investigations. Through the integration of XenoTech's specialized knowledge and product offerings, including microsomes and other laboratory models, BioIVT aims to strengthen its capacities in in-vitro toxicology assessments and pharmaceutical research. This move is expected to amplify BioIVT's competitive advantage within the sector. Additionally, in-silico is predicted to grow at fastest CAGR during the forecast period owing to the growing implementation of analytical method using computational tools for accurate and effective safety evaluation, and increasing technological developments.
By end-user, pharmaceutical industry was the highest revenue-grossing segment in the global in-vitro toxicology testing market in 2023 owing to a lot of toxicological testing is done to examine the pharmacokinetic characteristics of pharmaceutical medications, rising research & development for new drugs. Additionally, diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the growing number of diagnostic devices, increasing focus on development of innovative solutions for virus detection, and rising collaborations within market players. For instance, in March 2022, Laboratory Corporation of America Holdings (LabCorp) completed the acquisition of diagnostic clinical laboratory services provided by AtlantiCare.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing government funding for research & development activities, rising healthcare expenditure, growing adoption of toxicology testing, surge in launch of biologics by biopharmaceutical companies, and increasing mergers & acquisitions within market players. For instance, in June 2023, Lonza, a global manufacturing partner for pharmaceuticals, biotechnology, and nutraceuticals, has officially acquired Synaffix B.V., a biotechnology company specializing in advancing its clinical-stage technology platform for developing antibody-drug conjugates (ADCs). This strategic move is expected to support Lonza's expansion on a global scale. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising development of health care settings, growing geriatric population, surge in government investment for enhancing technology & development, and increasing collaborations within market players. For instance, in July 2023, InSphero AG and Cosmo Bio Co., Ltd. have formed a strategic partnership to distribute InSphero's innovative product range in Japan. This collaboration, which is now in effect, designates Cosmo Bio as the sole distributor of InSphero's 3D cell-based assay solutions throughout the Japanese market.
Segmentation: In-vitro Toxicology Testing Market Report 2022 - 2033
In-vitro Toxicology Testing Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Molecular Imaging
- Cell Culture Technology
- OMICS Technology
- High Throughput Technology
In-vitro Toxicology Testing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Dermal Toxicity
- Occular Toxicity
- Systemic Toxicology
- Endocrine Disruption
- Others
In-vitro Toxicology Testing Market Analysis & Forecast by Method 2023 - 2034 (Revenue USD Bn)
- Cellular Assay
- Fixed Cells
- Live Cells
- In-silico
- Biochemical Assay
- Ex-vivo
In-vitro Toxicology Testing Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Academic Institutes & Research Laboratories
- Cosmetics & Household Products
- Pharmaceutical Industry
- Food Industry
- Diagnostics
- Chemicals Industry
In-vitro Toxicology Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. In-vitro Toxicology Testing Market: Technology Estimates & Trend Analysis
8. In-vitro Toxicology Testing Market: Application Estimates & Trend Analysis
9. In-vitro Toxicology Testing Market: Method Estimates & Trend Analysis
10. In-vitro Toxicology Testing Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America In-vitro Toxicology Testing Market
13. Europe Global In-vitro Toxicology Testing Market
14. Asia Pacific Global In-vitro Toxicology Testing Market
15. Latin America Global In-vitro Toxicology Testing Market
16. MEA Global In-vitro Toxicology Testing Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Charles River Laboratories International Inc.
- Danaher Corporation
- Agilent Technolgies Inc.
- Merck KGaA
- SGS S.A.
- Evotec S.E.
- Thermo Fisher Scientific Inc.
- Gentronix
- Quest Diagnostics Incorporated
- Eurofins Scientific
- BioIVT
- Abbott Laboratories
- Catalent Inc.
- Bio-Rad Laboratories Inc
- Laboratory Corporation of America Holdings
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 31.34 Billion |
| Forecasted Market Value ( USD | $ 103.27 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
